Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 2, 2010, Pages 276-285

  Porada, C D ^a   Sanada, C ^a   Long, C R ^b   Wood, J A ^a   DesaI, J ^a   Frederick, N ^a   Millsap, L ^a   Bormann, C ^b   Menges, S L ^b   Hanna, C ^b   Flores Foxworth, G ^b   Shin, T ^b   Westhusin, M E ^b   Liu, W ^d   Glimp, H ^a   Zanjani, E D ^a   Lozier, J N ^e   Pliska, V ^c   Stranzinger, G ^c   Joerg, H ^c   Kraemer, D C ^b   Almeida Porada, G ^a   more..

^a UNIVERSITY OF NEVADA   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c ETH ZURICH   (Switzerland)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Hemophilia A; Inhibitors; Large animal model; Molecular characterization; Sheep

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; KOATE DVI; MESSENGER RNA; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BLEEDING; BLEEDING TIME; CAUSE OF DEATH; CONTROLLED STUDY; CRYOPRESERVATION; DISEASE MODEL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG RESPONSE; EXON; EXPERIMENTAL ANIMAL; FERTILIZATION IN VITRO; FRAMESHIFT MUTATION; GENE SEQUENCE; HEMARTHROSIS; HEMATURIA; HEMOPHILIA A; INTRACYTOPLASMIC SPERM INJECTION; MULTIPLE OVULATION AND EMBRYO TRANSFER; MUSCLE HEMATOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REPRODUCTIVE PROCEDURES; RESPIRATORY DISTRESS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROPERITONEAL HEMORRHAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SHEEP; SPERM PRESERVATION; STOP CODON; SYMPTOM; TREATMENT DURATION; UMBILICAL CORD;

AGE FACTORS; AGING; ANIMALS; BASE SEQUENCE; BLOOD COAGULATION; COAGULANTS; CODON, NONSENSE; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; EXONS; FACTOR VIII; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; REPRODUCTIVE TECHNIQUES, ASSISTED; RNA, MESSENGER; SHEEP; SPECIES SPECIFICITY;

EID: 74749088747     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03697.x     Document Type: Article

References (50)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001, 344:1773-9.
2. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001, 85:560.
3. Agaliotis D, Zaiden RA, Ozturk S, Besa EC. Hemophilia, Overview: eMedicine from WebMD, Medscape's continually updated clinical reference. 2006, In, ed, New York, WebMD, LLC
4. Kaveri SV, Dasgupta S, Andre S, Navarrete AM, Repesse Y, Wootla B, Lacroix-Desmazes S. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells. Haemophilia 2007, 13(Suppl. 5):61-4.
5. Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, Bellinger DA, Arruda VR, High KA. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J 2009, 50:144-67.
6. Arruda VR. Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models. J Thromb Haemost 2006, 4:1215-7.
7. Doering CB, Denning G, Dooriss K, Gangadharan B, Johnston JM, Kerstann KW, McCarty DA, Spencer HT. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A. Mol Ther 2009, 17:1145-54.
8. Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood 2008, 112:2713-21.
9. Ide LM, Gangadharan B, Chiang KY, Doering CB, Spencer HT. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood 2007, 110:2855-63.
10. Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, Kazazian H, Gaensler KM. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci USA 1999, 96:13324-9.
11. Ponder KP. Gene therapy for hemophilia. Curr Opin Hematol 2006, 13:301-7.
12. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995, 10:119-21.
13. Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996, 88:3446-50.
14. Hakobyan N, Kazarian T, Valentino LA. Synovitis in a murine model of human factor VIII deficiency. Haemophilia 2005, 11:227-32.
15. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004, 10:280-7.
16. Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, Schwarz HP. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost 1997, 77:591-9.
17. Hough C, Kamisue S, Cameron C, Notley C, Tinlin S, Giles A, Lillicrap D. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. Thromb Haemost 2002, 87:659-65.
18. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, Bellinger DA, Read M, Morgan RA. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proc Natl Acad Sci USA 2002, 99:12991-6.
19. Brooks MB, Barnas JL, Fremont J, Ray J. Cosegregation of a factor VIII microsatellite marker with mild hemophilia A in Golden Retriever dogs. J Vet Intern Med 2005, 19:205-10.
20. Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost 2004, 30:205-13.
21. High K. Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients? J Thromb Haemost 2005, 3:1682-91.
22. Pijnappels MI, Briet E, van der Zwet GT, Huisden R, van Tilburg NH, Eulderink F. Evaluation of the cuticle bleeding time in canine haemophilia A. Thromb Haemost 1986, 55:70-3.
23. Neuenschwander S, Kissling-Albrecht L, Heiniger J, Backfisch W, Stranzinger G, Pliska V. Inherited defect of blood clotting factor VIII (haemophilia A) in sheep. Thromb Haemost 1992, 68:618-20.
24. Backfisch W, Neuenschwander S, Giger U, Stranzinger G, Pliska V. Carrier detection of ovine hemophilia A using an RFLP marker, and mapping of the factor VIII gene on the ovine X-chromosome. J Hered 1994, 85:474-8.
25. Neuenschwander S, Pliska V. Factor VIII in blood plasma of haemophilic sheep: analysis of clotting time-plasma dilution curves. Haemostasis 1994, 24:27-35.
26. Zanjani ED, Pallavicini MG, Ascensao JL, Flake AW, Langlois RG, Reitsma M, MacKintosh FR, Stutes D, Harrison MR, Tavassoli M. Engraftment and long-term expression of human fetal hematopoietic stem cells in sheep following transplantation in utero. J Clin Invest 1992, 89:1178-88.
27. Perkett EA, Lyons RM, Moses HL, Brigham KL, Meyrick B. Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. J Clin Invest 1990, 86:1459-64.
28. Abraham WM. Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther 2008, 21:743-54.
29. Morrison JL. Sheep models of intrauterine growth restriction: fetal adaptations and consequences. Clin Exp Pharmacol Physiol 2008, 35:730-43.
30. Bormann C, Long C, Menges S, Hanna C, Foxworth G, Westhusin M, Pliska V, Stranzinger G, Glimp H, Millsap L, Porada C, Almeida-Porada G, Kraemer D. Reestablishment of an extinct strain of sheep utilizing assisted reproductive technologies. Reprod Fertil Dev 2007, 21:153.
31. Bormann C, Long C, Menges S, Hanna C, Foxworth G, Shin T, Westhusin M, Pliska V, Stranzinger G, Joerg H, Glimp H, Millsap L, Porada C, Almeida-Porada G, Kraemer D. Reestablishment of an extinct strain of sheep from a limited supply of frozen semen. Reprod Fertil Dev 2006, 18:201.
32. Shin T, Long C, Foxworth G, Hanna C, Menges S, Bormann C, Almeida-Porada G, Porada C, Glimp H, Millsap L, Westhusin M, Kraemer D. A simple modified ICSI technique resulting in high pregnancy rates in merino sheep (Ovis Aries). Society for the Study of Reproduction 2005
33. Triplett DA, Harms CS, Triplett DA. Coagulation screening assays. Procedures for the coagulation laboratory 1981, 1-21. In, ed, Chicago, American Society of Clinical Pathologists Press
34. Arkin CF, Bovil EG, Brandt JT, Rock WA, Triplett DA. Factors affecting the performance of Factor VIII coagulant activity assays. Arch Pathol Lab Med 1992, 116:908-15.
35. Benson R, Catalfamo JL, Dodds WJ. A multispecies enzyme-linked immunosorbent assay for von Willebrand's factor. J Lab Clin Med 1992, 119:420-7.
36. Jain N. Essentials of Veterinary Hematology 1993, Media: Williams and Wilkins
37. Williams W. Williams Hematology 2006, New York, McGraw-Hill Medical
38. Journeycake JM, Buchanan GR. Coagulation disorders. Pediatr Rev/Am Acad Pediatr 2003, 24:83-91.
39. Ananyeva NM, Lacroix-Desmazes S, Hauser CA, Shima M, Ovanesov MV, Khrenov AV, Saenko EL. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004, 15:109-24.
40. Littlewood JD, Barrowcliffe TW. The development and characterisation of antibodies to human factor VIII in haemophilic dogs. Thromb Haemost 1987, 57:314-21.
41. Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther 2000, 292:810-6.
42. Tomokiyo K, Teshima K, Nakatomi Y, Watanabe T, Mizuguchi J, Nozaki C, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S. Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B. Thromb Res 2001, 102:363-74.
43. Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC, McCarthy KP, Schaub RG, Nichols TC. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood 2003, 102:4393-8.
44. Xu L, Mei M, Haskins ME, Nichols TC, O'Donnell P, Cullen K, Dillow A, Bellinger D, Ponder KP. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thromb Res 2007, 120:269-80.
45. Aronson DL. Cause of death in hemophilia A patients in the United States from 1968 to 1979. Am J Hematol 1988, 27:7-12.
46. Chorba TL, Holman RC, Strine TW, Clarke MJ, Evatt BL. Changes in longevity and causes of death among persons with hemophilia A. Am J Hematol 1994, 45:112-21.
47. Miyasaka M, Trnka Z. Lymphocyte migration and differentiation in a large-animal model: the sheep. Immunol Rev 1986, 91:87-114.
48. Cinotti S, Paladino E, Morfini M. Accuracy of FVIII: C assay by one-stage method can be improved using hemophilic plasma as diluent. J Thromb Haemost 2006, 4:828-33.
49. Ovlisen K, Kristensen AT, Tranholm M. In vivo models of haemophilia - status on current knowledge of clinical phenotypes and therapeutic interventions. Haemophilia 2008, 14:248-59.
50. Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. A novel mutation (2409delT) in exon 14 of the factor VIII gene causes severe haemophilia A. Hum Hered 2000, 50:266-7.